Emerging drugs for the treatment of Myelofibrosis

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(12):1262–1271.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255–1265.
   PubMed Web of Science ®Google Scholar
• Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595–600.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981–2987.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood. 2017;129(7):832–837.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li C-Y, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973–977.
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Kaminskas E, Grillo J, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012;18(12):3212–3217.
   PubMed Web of Science ®Google Scholar
• Mascarenhas JO, Orazi A, Bhalla KN, et al. Advances in myelofibrosis: a clinical case approach. Haematologica. 2013;98(10):1499–1509.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–1477.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–1363.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–397.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061.
   PubMed Web of Science ®Google Scholar
• Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem. 2008;283(9):5258–5266.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128–1138.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28(2):431–433.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–1708.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395–1398.
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–4103.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Isola IM, Alvarez-Larrán A, et al. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol. 2015;94(11):1791–1796.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Alvarez-Larrán A, Hernández-Boluda J-C, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004;127(4):399–403.
   PubMed Web of Science ®Google Scholar
• Verstovsek, S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Harrison, C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.
   PubMed Web of Science ®Google Scholar
• Abgrall J-F, Guibaud I, Bastie J-N, et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica. 2006;91(8):1027–1032.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Elliott MA, Schroeder G, et al. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79(7):883–889.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158–1164.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011;118(4):899–902.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27(28):4760–4766.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol. 2010;85(2):129–130.
   PubMed Web of Science ®Google Scholar
• Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011;25(2):301–304.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Al-Ali HK, Barosi G, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017;31(4):896–902.
   PubMed Web of Science ®Google Scholar
• Kroger N. Outcome improvement after allogeneic stem-cell transplantation in myelofibrosis. J Oncol Pract. 2016;12(7):629–631.
   PubMed Web of Science ®Google Scholar
• Kroger, N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347–50; quiz 3364.
   PubMed Web of Science ®Google Scholar
• Kroger, N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264–5270.
   PubMed Web of Science ®Google Scholar
• Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124(7):1183–1191.
   PubMed Web of Science ®Google Scholar
• Hanif A, Hari PN, Atallah E, et al. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant. 2016;51(4):617–618.
   PubMed Web of Science ®Google Scholar
• Gupta V,Kosiorek H, Klisovic R et al. Exploring the potential of JAK1/2 inhibitor ruxolitinib with reduced intensity hematopoietic cell transplantation (HCT) for myelofibrosis: stage I results of a prospective trial conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC). Blood. 2016.128:1126
   PubMedGoogle Scholar
• Kuzanar W. American health and drug benefits : cost of treating patients with ruxolitinib. Health Econ. 2013;6(No.1 special issue). Available from: http://www.ahdbonline.com/issues/2013/february-2013-vol-6-no-1-special-issue/1289-article-1289
   Google Scholar
• Beggs J. Myelofibrosis market will exceed $1 billion by 2025, says GlobalData. Chem Cures. 2016. Available from: http://www.chemdiv.com/myelofibrosis-market-will-exceed-1-billion-2025-says-globaldata/
   Google Scholar
• Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322–1327.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kiladjian -J-J, Catalano JV, et al. Simplify-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis. J Clin Oncol. 2017;35(34):3844–3850.
   PubMed Web of Science ®Google Scholar
• Harrison, CN, Vannucchi AM, Platzbecker U, et al. Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). DOI: 10.1200/JCO.2017.35.15_suppl.7001. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 7001-7001.
   Google Scholar
• Verstovsek S, Odenike O, Singer JW, et al. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016;9(1):137.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225–e236.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J,Hoffman R, Talpaz M, et al. Results of the Persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts< 100,000/µl. Blood. 2016;128:LBA–5.
   Google Scholar
• Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009;114(24):5024–5033.
   PubMed Web of Science ®Google Scholar
• Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659–671.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Sandy L, Lu M, et al. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leuk Res. 2017;53:13–19.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Kiladjian J, Heidel F, et al. Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF). Blood. 2015;126(23):4060–4061.
   Web of Science ®Google Scholar
• Ribrag VT. A Phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with Primary Myelofibrosis (PMF), Post–polycythemia Vera MF (PPV-MF), or post–essential thrombocythemia MF (PET-MF): identification of the recommended Phase 2 dose. Blood. 2013;122:4045.
   Google Scholar
• Andersen CL, Mortensen NB, Klausen TW, et al. A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica. 2014;99(1):e5–7.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, Estrov Z, et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012;36(9):1124–1127.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008;22(5):965–970.
   PubMed Web of Science ®Google Scholar
• Odenike OM, Godwin JE, van Besien K, et al. Phase II study of decitabine in myelofibrosis with myeloid metaplasia. Blood. 2006;108:4923.
   Web of Science ®Google Scholar
• DaverN, Cortez J, Pemmaraju N, et al. Ruxolitinib (RUX) in combination with 5-azacytidine (AZA) as therapy for patients (pts) with myelofibrosis (MF). Blood. 2016;128:1127. American Society of Hematology.
   Web of Science ®Google Scholar
• RampalR,Mascarenhas J, Kosiorek H, et al. Safety and efficacy of combined ruxolitinib and decitabine in patients with blast-phase MPN and post-MPN AML: results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial). Blood. 2016;128:1127. American Society of Hematology.
   Web of Science ®Google Scholar
• XuN, Li Y, Zhou X, et al. LOXL2 highly-expressed induce the transition of stromal cells into cancer-associated fibroblasts which maybe involve in myeloproliferative neoplasms progession. Blood. 2015;126:5207. American Society of Hematology.
   Web of Science ®Google Scholar
• Mascarenhas J, Li T, Sandy L, et al. Anti-transforming growth factor-beta therapy in patients with myelofibrosis. Leuk Lymphoma. 2014;55(2):450–452.
   PubMed Web of Science ®Google Scholar
• Bose P, Daver N, Jabbour E, et al. Phase-2 study of sotatercept (ACE-011) in myeloproliferative neoplasm-associated myelofibrosis and anemia. Blood. 2016;128:478. American Society of Hematology.
   Web of Science ®Google Scholar
• VerstovsekS, Mesa R, Foltz L, et al. PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks. Blood. 2015;126:56. American Society of Hematology.
   Web of Science ®Google Scholar
• Duffield JS, Lupher ML. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010;23(5):305–315.
   PubMedGoogle Scholar
• VerstovsekS, Mesa R, Foltz L, et al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results. Blood. 2014;124:713. American Society of Hematology.
   Google Scholar
• Frankel A, Woo J, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
   Google Scholar
• Lasho T, Finke C, Kimlinger T, et al. Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. Blood. 2014;124:5577. American Society of Hematology.
   Web of Science ®Google Scholar
• Patnaik MM, Gupta V, Gotlib J, et al. Results from ongoing phase 2 trial of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms including chronic myelomonocytic leukemia. Blood. 2016;128:4245. American Society of Hematology.
   Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6(11):836–848.
   PubMed Web of Science ®Google Scholar
• Lu M, Zhang W, Li Y, et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010;38(6):472–480.
   PubMed Web of Science ®Google Scholar
• Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988;2(8607):403.
   PubMed Web of Science ®Google Scholar
• Silver RT, Vandris K. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukemia. 2009;23(7):1366–1369.
   PubMed Web of Science ®Google Scholar
• IanottoJC, Kiladjian J, Demory J, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d’Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol. 2009;146(2):223–225.
   PubMedGoogle Scholar
• Mikkelsen SU, Kjor L, Skov V, et al. Safety and efficacy of combination therapy of interferon-Alpha2 + JAK1-2 inhibitor in the philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from the Danish Combi-Trial - an open label, single arm, non-randomized multicenter Phase II study. Am Soc Hematol. 2015.
   Google Scholar
• Bernard L, Belisle C, Mollica L et al. Telomere length is severely and similarly reduced in jak2v617f-positive and -negative myeloproliferative neoplasms. Leukemia. 2009;23(2):287–291.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373(10):908–919.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Carter B, Kantarjian H, et al. Results for phase II clinical trial of LCL161, a SMAC mimetic, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF) or post-essential thrombocytosis myelofibrosis (post-ET MF). Blood. 2016;128:3105. American Society of Hematology.
   Web of Science ®Google Scholar
• Gupta V, Harrison C, Hasselbalch H, et al. Phase 1b/2 study of the efficacy and safety of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. Blood. 2015;126:825. American Society of Hematology.
   PubMed Web of Science ®Google Scholar
• Pinton L, Solito S, Damuzzo V, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget. 2016;7(2):1168–1184.
   PubMedGoogle Scholar
• Daver N, Basu S, Garcia M, et al. Defining the immune checkpoint landscape in patients with acute myeloid leukemia. Blood. 2016;128:2900.
   Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105–111.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494–1500.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Finke C, et al. Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis. Blood. 2014;124(21):406.
   Web of Science ®Google Scholar
• Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT Project. Blood. 2014;124(21):405.
   Web of Science ®Google Scholar
• MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2017;JCO2017764886.
   Google Scholar